Discovery of Novel Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) Inhibitors for Cancer Treatment-Reference-Cited by-同舟云学术

Discovery of Novel Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) Inhibitors for Cancer Treatment

Published:2024-06-24 Issue:13 Volume:67 Page:10655-10686
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Luo Dongdong¹,Qiu Xingyang¹^ORCID,Zheng Qingquan¹,Ming Yue¹,Pu Wencheng¹^ORCID,Ai Ming¹,He Jianhua¹,Peng Yong¹²^ORCID

Affiliation:

1. Laboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610064, China

2. Frontier Medical Center, Tianfu Jincheng Laboratory, Chengdu 610212, China

Funder

West China Hospital, Sichuan University

National Key Research and Development Program of China

China Postdoctoral Science Foundation

Science and Technology Department of Sichuan Province

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00175

Reference49 articles.

1. Receptor tyrosine kinase inhibitors in cancer

2. Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders

3. Spatial regulation of receptor tyrosine kinases in development and cancer

4. Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer

5. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions;Cancers;2024-08-19

2. Novel humanized monoclonal antibodies against ROR1 for cancer therapy;Molecular Cancer;2024-08-13

3. Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies;Science China Life Sciences;2024-08-12